Table 1. Demographic and Baseline Characteristics of EV-301 and THOR Before and After Matching.
| EV-301 (N=608) | THOR (N=266) |
THOR
Exclusion Criteria Applied (n = 197) |
THOR
Matched (n = 197, ESS = 126) |
|
|---|---|---|---|---|
| Bellmunt risk score (%) | ||||
| 0-1 | 68 | 74 | 78 | 68 |
| 2 | 32 | 26 | 22 | 32 |
| ECOG PS (%) | ||||
| 0 | 40 | 43 | 48 | 40 |
| 1 | 60 | 48 | 52 | 60 |
| Presence of liver metastasis (%) | 25 | 26 | 26 | 25 |
| Presence of visceral metastasis (%) | 66 | 74 | 76 | 66 |
| Origin of primary disease (%) | ||||
| Upper urinary tract | 34 | 33 | 35 | 34 |
| Bladder or other site | 66 | 67 | 65 | 66 |
| Smoking status (%) | ||||
| Never smoked | 33 | 34 | 31 | 33 |
| History of diabetes or hyperglycemia (%) | 19 | 12 | 12 | 19 |
| Region (%) | ||||
| Western Europe | 42 | 61 | 60 | 42 |
| United States | 14 | 5 | 5 | 14 |
| Other | 44 | 34 | 36 | 44 |
| Age, y (%) | ||||
| <75 | 68 | 67 | 67 | 68 |
| ≥75 | 20 | 21 | 20 | 20 |
| Sex, male (%) | 77 | 71 | 71 | 77 |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance score; ESS, effective sample size, SMD, standardized mean difference.